title: Outcomes of thrombolysis with and without predilation of the inferior vena cava (IVC) in patients with Budd-Chiari syndrome with old IVC thrombosis.
abstract: OBJECTIVE
  To compare the efficacy of thrombolysis with and without predilation of the inferior vena cava (IVC) for Budd-Chiari syndrome (BCS) with old IVC thrombosis.
  
  
  METHODS
  We divided 40 patients with BCS with old IVC thrombosis into 2 groups, group A (n = 21), thrombolysis after dilation of the obstructed IVC and group B (n = 19), thrombolysis without predilation of the obstructed IVC. Thrombolysis was performed via urokinase administration through the dorsal vein of the foot.
  
  
  RESULTS
  Color Doppler ultrasonography at 30 days showed complete resolution of the thrombus in 21 (100%) group A patients and 6 group B patients (31.6%; P < .001). Thrombolysis was achieved using a lower dose of urokinase and within a shorter time frame in group A than in group B (P < .001).
  
  
  CONCLUSIONS
  Thrombolysis after dilation was superior to thrombolysis alone and was safe and efficacious in patients with BCS with old IVC thrombosis.
authors: Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.
authors: Jian-Zhuang
authors: JZ
authors: Ren
authors: Guo-Hao
authors: GH
authors: Huang
authors: Peng-Xu
authors: PX
authors: Ding
authors: Gang
authors: G
authors: Wu
authors: Xin-Wei
authors: XW
authors: Han
authors: Yan-Li
authors: YL
authors: Wang
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000368:Aged; D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000295:instrumentation; D006502:Budd-Chiari Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010690:Phlebography; D011237:Predictive Value of Tests; D015912:Thrombolytic Therapy / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D018615:Ultrasonography, Doppler, Color; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D062666:Vascular Access Devices; D014682:Vena Cava, Inferior / Q000000981:diagnostic imaging
chemical_list: D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator